Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (428)	8/27/1999 10:42:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Rick, I think you got the 25% number from the fact that TTP has a royalty payment to Hoechst Marion Roussel and the combined two represent a 25% royalty. In reality it isn't a 25% royalty but rather TTP gets 10% and then they pay Hoechst 15% of their 10%. I will try to get a clarification on this next week. As a side note to this issue, TTP did keep the right for Japan with Novartis having everything else. But again, the market worldwide is in the multi-billions.

To: scaram(o)uche who wrote (428)	8/30/1999 12:22:00 AM
From: RCMac	Read Replies (1) \| Respond to of 626

10%, not 25% royalty on ilo. As Emily Litella used to say, Never Mind. Ouch, ooooch. (Actually, not quite never mind - reduce the earnings and share price targets in my giddy projections by 60%. 10% of $600 million is a $60 million royalty / 24.7 M shares = $2.43/share. With a 35 PE (probably low), about $85/share based on ilo alone. Still not too shabby.) I'm embarrassed that I didn't catch the error in 25% before I posted - I sort of registered that 25% was better than I remembered, but in the good cheer of Friday afternoon -- the end of a terrific week in TTP, CLTR and PCYC (and Ann Arbor weather), and I'd seen you and Peter having some fun doing missionary work among the "jerk daytraders" on the BCRX thread Message 11084513 and Message 11086008 - I didn't pause to check. For my penance, I've tracked down some references to the ilo royalty rate, which turn out to be pretty equivocal. Peter reports the "consensus": >> The [iloperidone] deal is somewhat unusual, because the drug was developed by HMR, licensed to TTP and then licensed to Novartis. The consensus on the threads is that Novartis will pay a 15% royalty to HMR and 10% to TTP. (I have no personal knowledge of the accuracy of these numbers).<< Message 8082836 TexasDude gives the ilo royalty number as 10% in the introduction to this thread, which number appears to derive from Sturza's admitted estimate, see this from 2/98: Message 3448999 ("an undisclosed royalty on net product sales, which we estimate will be in the 10% range.") None of the sources I've found here are unequivocal, and they may all stem from Sturza's "estimate", not from anyone's actual knowledge. Which raises the question, do we know the royalty rate with any firmness, or do we have just a "consensus", just "received wisdom" flowing from Sturza's (possibly wide) estimate? Any thoughts? Any better knowledge? --Bob